

(12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织
国际局



(10) 国际公布号
WO 2020/216188 A1

(43) 国际公布日
2020 年 10 月 29 日 (29.10.2020)

(51) 国际专利分类号:
C07D 215/22 (2006.01) *A61P 35/00* (2006.01)
A61K 31/47 (2006.01)

(21) 国际申请号: PCT/CN2020/085695

(22) 国际申请日: 2020 年 4 月 20 日 (20.04.2020)

(25) 申请语言: 中文

(26) 公布语言: 中文

(30) 优先权:
201910324939.6 2019 年 4 月 22 日 (22.04.2019) CN

(71) 申请人: 北京康辰药业股份有限公司 (BEIJING KONRUNS PHARMACEUTICAL CO., LTD.) [CN/CN]; 中国北京市密云区经济开发区兴盛南路 11 号, Beijing 101500 (CN)。

(72) 发明人: 孙效华 (SUN, Xiaohua); 中国北京市密云区经济开发区兴盛南路 11 号, Beijing 101500 (CN)。王龙 (WANG, Long); 中国北京市密云区经济开发区兴盛南路 11 号, Beijing 101500 (CN)。杨红振 (YANG, Hongzhen); 中国北京市密云区经济开发区兴盛南路 11 号, Beijing 101500 (CN)。胡怀忠 (HU, Huaizhong); 中国北京市密云区经济开发区兴盛南路 11 号, Beijing 101500 (CN)。

(74) 代理人: 北京汇思诚业知识产权代理有限公司 (UNI-INTEL PATENT AND TRADEMARK LAW FIRM); 中国北京市朝阳区建国门外大街永安东里甲 3 号通用国际中心 A 座 3 层, Beijing 100022 (CN)。

(81) 指定国 (除另有指明, 要求每一种可提供的国家保护): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU,

(54) Title: CRYSTAL FORMS OF COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

(54) 发明名称: 化合物晶型、其制备方法、药物组合物以及应用




图 3

(57) Abstract: Provided by the present invention are three crystal forms of a compound 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxy-7-quinolinyl]oxy]hexanoic acid used in the treatment of diseases related to protein kinase AXL and/or VEGFR2, the crystal forms comprising: crystal form AB, crystal form M and crystal form F. Further provided by the present invention is a method used for preparing the three crystal forms and a pharmaceutical composition containing the three crystal forms. The crystal form AB, crystal form M and crystal form F of the present invention all have good chemical stability. In addition, the preparation method for the three crystal forms of the present invention is simple and easy to implement, the yield and purity of the products are high, and said products can be produced stably in batches, which is beneficial for promotion and application. The crystal form AB, crystal form M and crystal form F of the present invention are also relatively stable under high temperature, high humidity, and oxidation conditions, which is beneficial both for storage and transportation, and which is

[见续页]

WO 2020/216188 A1

CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW。

(84) 指定国 (除另有指明, 要求每一种可提供的地区保护): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), 欧亚 (AM, AZ, BY, KG, KZ, RU, TJ, TM), 欧洲 (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)。

本国际公布:

— 包括国际检索报告 (条约第21条(3))。

beneficial for industrial production. In addition, the crystal form AB, crystal form M and crystal form F of the present invention have high bioavailability, and meet the requirements of clinical medication.

(57) 摘要: 本发明提供了用于治疗蛋白激酶AXL和/或VEGFR2相关疾病的化合物6-[[4-[2-氟-4-[[1-[(4-氟苯基)氨基甲酰基]环丙烷羰基]氨基]苯氧基]-6-甲氧基-7-喹啉基]氧基]己酸的三种晶型: 晶型AB、晶型M和晶型F。本发明还提供了用于制备这三种晶型的方法及包含这三种晶型的药物组合物。本发明的晶型AB、晶型M和晶型F均具有良好的化学稳定性, 并且本发明的三种晶型的制备方法简单易行, 产物收率和纯度高, 能够稳定且批量化生产, 有利于推广和应用。本发明的晶型AB、晶型M、晶型F在高温、高湿、氧化条件下也较为稳定, 有利于储存和运输, 有利于工业化生产。此外, 本发明的晶型AB、晶型M和晶型F具有较高的生物利用度, 符合临床用药要求。